Your shopping cart is currently empty

Semaglutide-d8 is the deuterium-labeled form of Semaglutide. Semaglutide, a long-acting, selective, competitive GLP-1R agonist, can cross the blood-brain barrier. Upon GLP-1R activation, it promotes insulin secretion, inhibits gastric emptying and appetite, and enhances autophagy while suppressing oxidative stress and apoptosis. It also regulates mitochondrial function and lipid metabolism, such as reducing hepatic de novo lipogenesis. Semaglutide exhibits activities like lowering blood glucose, weight reduction, neuroprotection (e.g., improving motor function in Parkinson’s models and reducing α-synuclein aggregation), and amelioration of hepatic steatosis. It is used in the research of type 2 diabetes, obesity, Parkinson’s disease, metabolic-associated steatotic liver disease (MASLD), other neurodegenerative diseases, liver disorders, and cancer.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | Semaglutide-d8 is the deuterium-labeled form of Semaglutide. Semaglutide, a long-acting, selective, competitive GLP-1R agonist, can cross the blood-brain barrier. Upon GLP-1R activation, it promotes insulin secretion, inhibits gastric emptying and appetite, and enhances autophagy while suppressing oxidative stress and apoptosis. It also regulates mitochondrial function and lipid metabolism, such as reducing hepatic de novo lipogenesis. Semaglutide exhibits activities like lowering blood glucose, weight reduction, neuroprotection (e.g., improving motor function in Parkinson’s models and reducing α-synuclein aggregation), and amelioration of hepatic steatosis. It is used in the research of type 2 diabetes, obesity, Parkinson’s disease, metabolic-associated steatotic liver disease (MASLD), other neurodegenerative diseases, liver disorders, and cancer. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.